N. Wood

发表

Measurement of Cerebral Monoamine Oxidase B Activity Using L-[11C]Deprenyl and Dynamic Positron Emission Tomography

R. Frackowiak, C. Bench, A. Lammertsma, 1991, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

Pharmacokinetics and Safety of Voriconazole following Intravenous- to Oral-Dose Escalation Regimens

N. Wood, P. Ghahramani, L. Purkins, 2002, Antimicrobial Agents and Chemotherapy.

The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human.

N. Wood, D. Smith, D. Walker, 2003, Drug metabolism and disposition: the biological fate of chemicals.

Voriconazole does not affect the steady-state pharmacokinetics of digoxin.

N. Wood, L. Purkins, D. Kleinermans, 2003, British journal of clinical pharmacology.

Equivalent Systemic Exposure to Fluticasone Propionate/Salmeterol Following Single Inhaled Doses from Advair Diskus and Wixela Inhub: Results of Three Pharmacokinetic Bioequivalence Studies

N. Wood, S. Haughie, R. Allan, 2020, Journal of aerosol medicine and pulmonary drug delivery.

Voriconazole potentiates warfarin-induced prothrombin time prolongation.

N. Wood, L. Purkins, D. Kleinermans, 2003, British journal of clinical pharmacology.

The pharmacokinetics and safety of intravenous voriconazole - a novel wide-spectrum antifungal agent.

N. Wood, S. Oliver, M. Eve, 2003, British journal of clinical pharmacology.

Effect of omeprazole on the steady-state pharmacokinetics of voriconazole.

N. Wood, G. Layton, Keith Tan, 2003, British journal of clinical pharmacology.

The influence of levodopa on gastric emptying in man.

J. Fleming, N. Wood, A. Renwick, 1990, British journal of clinical pharmacology.

Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety.

N. Wood, S. Oliver, L. Purkins, 2003, British journal of clinical pharmacology.

Effects of Hepatic Dysfunction on the Single‐Dose Pharmacokinetics of Fesoterodine

N. Wood, Z. Krastev, B. Malhotra, 2011, Journal of clinical pharmacology.

Pharmacokinetics and Safety of Intravenous Voriconazole in Children after Single- or Multiple-Dose Administration

M. Karlsson, P. Adamson, N. Wood, 2004, Antimicrobial Agents and Chemotherapy.

Population pharmacokinetic–pharmacodynamic modelling of the relationship between testosterone and prostate specific antigen in patients with prostate cancer during treatment with leuprorelin

N. Wood, M. Hibberd, G. Scott, 2019, British journal of clinical pharmacology.

Pharmacokinetics, Safety, and Tolerability of Voriconazole in Immunocompromised Children

H. Jafri, N. Wood, N. Klein, 2010, Antimicrobial Agents and Chemotherapy.

Clinical pharmacology of moclobemide during chronic administration of high doses to healthy subjects

N. Wood, R. Amrein, J. Dingemanse, 1998, Psychopharmacology.

Inhibition of brain monoamine oxidase-B by Ro19-6327 — in vivo measurerment using positron emission tomography

R. Frackowiak, A. Lammertsma, S. Luthra, 1990 .

Effects of Multiple Doses of Voriconazole on the Vision of Healthy Volunteers: A Double-Blind, Placebo-Controlled Study

E. Zrenner, N. Wood, G. Layton, 2014, Ophthalmic Research.

Investigation of the Potential Relationships Between Plasma Voriconazole Concentrations and Visual Adverse Events or Liver Function Test Abnormalities

N. Wood, Keith Tan, P. Troke, 2006, Journal of clinical pharmacology.

Coadministration of voriconazole and phenytoin: pharmacokinetic interaction, safety, and toleration.

N. Wood, P. Ghahramani, A. Fielding, 2003, British journal of clinical pharmacology.

Effect of food on the pharmacokinetics of multiple-dose oral voriconazole.

N. Wood, L. Purkins, K. Greenhalgh, 2003, British journal of clinical pharmacology.

Safety of voriconazole and dose individualization.

N. Wood, I. Lutsar, M. Hodges, 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Pharmacokinetics of Voriconazole Administered Concomitantly with Fluconazole and Population-Based Simulation for Sequential Use

N. Wood, M. Varma, B. Damle, 2011, Antimicrobial Agents and Chemotherapy.

Single-or Multiple-Dose Administration Intravenous Voriconazole in Children after Pharmacokinetics and Safety of

M. Karlsson, P. Adamson, N. Wood, 2004 .

The effect of age on the pharmacokinetics of levodopa administered alone and in the presence of carbidopa.

A G Renwick, D G Waller, N. Wood, 1989, British journal of clinical pharmacology.

Effect of voriconazole on the pharmacokinetics of cyclosporine in renal transplant patients

N. Wood, L. Nilsson, A. Romero, 2002, Clinical pharmacology and therapeutics.

No clinically significant pharmacokinetic interactions between voriconazole and indinavir in healthy volunteers.

N. Wood, L. Purkins, D. Kleinermans, 2003, British journal of clinical pharmacology.

No clinically significant effect of erythromycin or azithromycin on the pharmacokinetics of voriconazole in healthy male volunteers.

N. Wood, G. Layton, P. Ghahramani, 2003, British journal of clinical pharmacology.

Population Pharmacokinetic Meta-Analysis to Bridge Ferumoxytol Plasma Pharmacokinetics Across Populations

N. Wood, A. Facius, G. Lahu, 2014, Clinical Pharmacokinetics.

Pharmacokinetics, Safety and Tolerance of Voriconazole in Renally Impaired Subjects

D. Webb, N. Wood, K. Gandelman, 2008, Clinical drug investigation.

Pharmacokinetics of sulfobutylether-β-cyclodextrin (SBECD) in subjects on hemodialysis.

N. Wood, B. Damle, D. Luke, 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Histamine H2-receptor antagonists have no clinically significant effect on the steady-state pharmacokinetics of voriconazole.

N. Wood, L. Purkins, D. Kleinermans, 2003, British journal of clinical pharmacology.

The design and development of fesoterodine as a prodrug of 5-hydroxymethyl tolterodine (5-HMT), the active metabolite of tolterodine.

N. Wood, B. Malhotra, K. Gandelman, 2009, Current medicinal chemistry.

Influence of age, gender, and race on pharmacokinetics, pharmacodynamics, and safety of fesoterodine.

N. Wood, B. Malhotra, R. Sachse, 2009, International journal of clinical pharmacology and therapeutics.

Thorough QT study of the effect of fesoterodine on cardiac repolarization.

N. Wood, B. Malhotra, K. Gandelman, 2010, International journal of clinical pharmacology and therapeutics.

Influence of food on the pharmacokinetic profile of fesoterodine.

N. Wood, B. Malhotra, R. Sachse, 2009, International journal of clinical pharmacology and therapeutics.

Assessment of the Effects of Renal Impairment on the Pharmacokinetic Profile of Fesoterodine

N. Wood, B. Malhotra, K. Gandelman, 2009, Journal of clinical pharmacology.

Pharmacokinetic profile of fesoterodine.

N. Wood, B Malhotra, B. Malhotra, 2008, International journal of clinical pharmacology and therapeutics.

Pharmacokinetics and pharmacodynamics of single and multiple doses of the MAO-B inhibitor lazabemide in healthy subjects.

N. Wood, J. Dingemanse, R. Kettler, 1997, British journal of clinical pharmacology.

Measurement of human cerebral monoamine oxidase type B (MAO-B) activity with positron emission tomography (PET): a dose ranging study with the reversible inhibitor Ro 19-6327

R. Dolan, R. Frackowiak, C. Bench, 2004, European Journal of Clinical Pharmacology.

Evaluation of drug–drug interactions with fesoterodine

N. Wood, B. Malhotra, Nolan Wood, 2009, European Journal of Clinical Pharmacology.

Pharmacokinetics of Voriconazole Administered Concomitantly with

N. Wood, M. Varma, Pfizer Ltd, 2011 .

Effect of voriconazole on the pharmacokinetics of omeprazole

N. Wood, A. Fielding, D. Nichols, 2001 .